TALS
TALARIS THERAPEUTICS INC
1 day chart
About TALS
Talaris Therapeutics, Inc. is a late-clinical stage cell therapy company. The Company is engaged in developing allogeneic hematopoietic stem cell transplantation (allo-HSCT). The Company is advancing a pipeline of programs across three therapeutic categories: solid organ transplantation, severe autoimmune disease, and severe non-malignant blood, immune and metabolic disorders. Its therapeutic approach, allo-HSCT therapy prevents organ rejection without the morbidity and mortality that has been associated with the use of anti-rejection medicines, also known as chronic immunosuppression. Allo-HSCT is used to replace diseased immune, blood or stem cells in patients with severe immune, blood or metabolic disorders. The Company’s lead product candidate, FCR001, which is central to its Facilitated Allo-HSCT Therapy, is an allogeneic cell therapy comprised of stem and immune cells that are procured from a healthy donor, who is also the organ donor in the case of organ transplantation.
Buy US stocks in Australia starting with TALS. Open an account and start investing today!
$122.87M
-
0.00%
67.28K
$2.92
$2.83
$2.89
$3.29
$0.89
TALS FAQs
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in TALS
Related Stocks
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.